PTK2 and familial pancreatic carcinoma: In previous studies, we screened a series of new FAK inhibitors with imidazo[1,2-b]pyridine pharmacophore structures, thereby demonstrating promising anticancer activity in several preclinical models of pancreatic cancer, including primary cultures[24].